{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:13:01Z","timestamp":1788952381324,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.","award":["1401\/59212"],"award-info":[{"award-number":["1401\/59212"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04549-3","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:03:13Z","timestamp":1740103393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Elaheh","family":"Rashidbeygi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Rasaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieh","family":"Salavatizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mohammadizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita","family":"Hekmatdoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"4549_CR1","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.ebiom.2024.105127","volume":"103","author":"C Hateley","year":"2024","unstructured":"Hateley C, Olona A, Halliday L, Edin ML, Ko JH, Forlano R, Terra X, Lih FB, Beltr\u00e1n-Deb\u00f3n R, Manousou P, et al. Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide:diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity. EBioMedicine. 2024;103:105127.","journal-title":"EBioMedicine"},{"issue":"7121","key":"4549_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860\u20137.","journal-title":"Nature"},{"key":"4549_CR3","doi-asserted-by":"publisher","first-page":"104964","DOI":"10.1016\/j.ebiom.2023.104964","volume":"100","author":"W Liu","year":"2024","unstructured":"Liu W, Yang C, Lei F, Huang X, Cai J, Chen S, She ZG, Li H. Major lipids and lipoprotein levels and risk of blood pressure elevation: a mendelian randomisation study. EBioMedicine. 2024;100:104964.","journal-title":"EBioMedicine"},{"issue":"1","key":"4549_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","volume":"35","author":"KN Lazaridis","year":"2001","unstructured":"Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019. J Hepatol. 2001;35(1):134\u201346.","journal-title":"J Hepatol"},{"issue":"3","key":"4549_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"G Paumgartner","year":"2002","unstructured":"Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525\u201331.","journal-title":"Hepatology"},{"key":"4549_CR6","unstructured":"Organization WH. World Health Organization Obesity and Overweight. In.; 2011."},{"key":"4549_CR7","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. 2016."},{"issue":"9369","key":"4549_CR8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(03)13302-8","volume":"361","author":"JA Staessen","year":"2003","unstructured":"Staessen JA, Wang J, Bianchi G, Birkenh\u00e4ger WH. Essential hypertension. Lancet. 2003;361(9369):1629\u201341.","journal-title":"Lancet"},{"issue":"9","key":"4549_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7326\/0003-4819-139-9-200311040-00011","volume":"139","author":"S Oparil","year":"2003","unstructured":"Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139(9):761\u201376.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4549_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","volume":"8","author":"G Paumgartner","year":"2004","unstructured":"Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004;8(1):67\u201381. vi.","journal-title":"Clin Liver Dis"},{"issue":"5","key":"4549_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"8","key":"4549_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1248\/bpb.b16-00094","volume":"39","author":"A Cao","year":"2016","unstructured":"Cao A, Wang L, Chen X, Guo H, Chu S, Zhang X, Peng W. Ursodeoxycholic acid ameliorated diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress. Biol Pharm Bull. 2016;39(8):1300\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"4549_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1046\/j.1365-2125.1999.00940.x","volume":"47","author":"J Sinisalo","year":"1999","unstructured":"Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS. Ursodeoxycholic acid and endothelial-dependent, nitric oxide\u2010independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol. 1999;47(6):661\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4549_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gut.2011.237974","volume":"60","author":"VW-S Wong","year":"2011","unstructured":"Wong VW-S, Wong GL-H, Tsang SW-C, Fan T, Chu WC-W, Woo J, Chan AW-H, Choi PC-L, Chim AM-L. Lau JY-W: high prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60(6):829\u201336.","journal-title":"Gut"},{"issue":"5","key":"4549_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.cell.2015.02.010","volume":"160","author":"ME Kotas","year":"2015","unstructured":"Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015;160(5):816\u201327.","journal-title":"Cell"},{"key":"4549_CR16","doi-asserted-by":"crossref","unstructured":"B\u00e4ck M, Topouchian J, Labat C, Gautier S, Blacher J, Cwynar M, de la Sierra A, Pall D, Duarte K, Fantin F et al. Cardio-ankle vascular index for predicting cardiovascular morbimortality and determinants for its progression in the prospective advanced approach to arterial stiffness (TRIPLE-A-Stiffness) study. eBioMedicine 2024, 103.","DOI":"10.1016\/j.ebiom.2024.105107"},{"issue":"7347","key":"4549_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317\u201325.","journal-title":"Nature"},{"issue":"2","key":"4549_CR18","doi-asserted-by":"publisher","first-page":"G334","DOI":"10.1152\/ajpgi.00406.2015","volume":"311","author":"AM O\u2019Dwyer","year":"2016","unstructured":"O\u2019Dwyer AM, Lajczak NK, Keyes JA, Ward JB, Greene CM, Keely SJ. Ursodeoxycholic acid inhibits TNF\u03b1-induced IL-8 release from monocytes. Am J Physiology-Gastrointestinal Liver Physiol. 2016;311(2):G334\u201341.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"4","key":"4549_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, Van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463\u201372.","journal-title":"Gut"},{"issue":"6","key":"4549_CR20","doi-asserted-by":"publisher","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","volume":"312","author":"JB Ward","year":"2017","unstructured":"Ward JB, Lajczak NK, Kelly OB, O\u2019Dwyer AM, Giddam AK, N\u00ed Gabhann J, Franco P, Tambuwala MM, Jefferies CA, Keely S. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiology-Gastrointestinal Liver Physiol. 2017;312(6):G550\u20138.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"1","key":"4549_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1\u20139.","journal-title":"Syst Reviews"},{"issue":"3","key":"4549_CR22","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. Acp j club. 1995;123(3):A12\u20133.","journal-title":"Acp j club"},{"key":"4549_CR23","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org 2011."},{"key":"4549_CR24","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials control clin trials. 1986, 177(10).","DOI":"10.1016\/0197-2456(86)90046-2"},{"issue":"8","key":"4549_CR25","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/j.1478-3231.2009.02037.x","volume":"29","author":"ML Balmer","year":"2009","unstructured":"Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29(8):1184\u20138.","journal-title":"Liver Int"},{"issue":"6","key":"4549_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jacc.2011.10.880","volume":"59","author":"S Von Haehling","year":"2012","unstructured":"Von Haehling S, Schefold JC, Jankowska EA, Springer J, Vazir A, Kalra PR, Sandek A, Fauler G, Stojakovic T, Trauner M. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012;59(6):585\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4549_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):1\u201310.","journal-title":"BMC Med Res Methodol"},{"key":"4549_CR28","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Wiley; 2021.","DOI":"10.1002\/9781119558378"},{"key":"4549_CR29","unstructured":"GetData G. Digitizer version 2.24 [Get data-graph-digitizer-com]."},{"issue":"11","key":"4549_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7414","key":"4549_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"4549_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"12","key":"4549_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1155\/2003\/857869","volume":"17","author":"M Kiyici","year":"2003","unstructured":"Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol = J canadien de gastroenterologie. 2003;17(12):713\u20138.","journal-title":"Can J Gastroenterol = J canadien de gastroenterologie"},{"issue":"1","key":"4549_CR34","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/bmjdrc-2017-000469","volume":"6","author":"KR Shima","year":"2018","unstructured":"Shima KR, Ota T, Kato KI, Takeshita Y, Misu H, Kaneko S, Takamura T. Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. BMJ open Diabetes Res care. 2018;6(1):e000469.","journal-title":"BMJ open Diabetes Res care"},{"issue":"6","key":"4549_CR35","first-page":"1484","volume":"23","author":"C Colombo","year":"1996","unstructured":"Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the study of Ursodeoxycholic Acid in cystic fibrosis. Hepatology (Baltimore MD). 1996;23(6):1484\u201390.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"3","key":"4549_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4103\/ejs.ejs_29_18","volume":"37","author":"TA Abouzeid","year":"2018","unstructured":"Abouzeid TA, Shoka AA. Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial. Egypt J Surg. 2018;37(3):349\u201354.","journal-title":"Egypt J Surg"},{"key":"4549_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12072-012-9387-y","volume":"7","author":"V Gianturco","year":"2013","unstructured":"Gianturco V, Troisi G, Bellomo A, Bernardini S, D\u2019Ottavio E, Formosa V, Iacono CL, Verrusio W, Marigliano B, Marigliano V. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hep Intl. 2013;7:570\u20136.","journal-title":"Hep Intl"},{"issue":"2","key":"4549_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.23727","volume":"52","author":"UF Leuschner","year":"2010","unstructured":"Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, R\u00f6ssle M, Cordes HJ, Zeuzem S, Hein J, Berg T, Group NS. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double\u2010blind, randomized, placebo\u2010controlled trial. Hepatology. 2010;52(2):472\u20139.","journal-title":"Hepatology"},{"issue":"3","key":"4549_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770\u20138.","journal-title":"Hepatology"},{"key":"4549_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/BF02093811","volume":"41","author":"JW Marks","year":"1996","unstructured":"Marks JW, Bonorris GG, Schoenfield LJ. Effects of ursodiol or ibuprofen on contraction of gallbladder and bile among obese patients during weight loss. Dig Dis Sci. 1996;41:242\u20139.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"4549_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1665-2681(19)32103-9","volume":"3","author":"N M\u00e9ndez-S\u00e1nchez","year":"2004","unstructured":"M\u00e9ndez-S\u00e1nchez N, Gonz\u00e1lez V, Ch\u00e1vez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol. 2004;3(3):108\u201312.","journal-title":"Ann Hepatol"},{"issue":"5","key":"4549_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/01.sla.0000094305.77843.cf","volume":"238","author":"K Miller","year":"2003","unstructured":"Miller K, Hell E, Lang B, Lengauer E. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg. 2003;238(5):697.","journal-title":"Ann Surg"},{"key":"4549_CR43","doi-asserted-by":"crossref","unstructured":"Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers* FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med. 1995;122(12):899\u2013905.","DOI":"10.7326\/0003-4819-122-12-199506150-00002"},{"issue":"1","key":"4549_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9610(99)80115-9","volume":"169","author":"HJ Sugerman","year":"1995","unstructured":"Sugerman HJ, Brewer WH, Shiffman ML, Brolin RE, Fobi MA, Linner JH, MacDonald KG, MacGregor AM, Martin LF, Oram-Smith JC. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 1995;169(1):91\u20137.","journal-title":"Am J Surg"},{"issue":"2","key":"4549_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000007742","volume":"61","author":"P Schiedermaier","year":"2000","unstructured":"Schiedermaier P, Hansen S, Asdonk D, Brensing K-A, Sauerbruch T. Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. Digestion. 2000;61(2):107\u201312.","journal-title":"Digestion"},{"issue":"7075","key":"4549_CR46","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484\u20139.","journal-title":"Nature"},{"issue":"3","key":"4549_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000450982","volume":"35","author":"A Wahlstr\u00f6m","year":"2017","unstructured":"Wahlstr\u00f6m A, Kovatcheva-Datchary P, St\u00e5hlman M, B\u00e4ckhed F, Marschall H-U. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling. Dig Dis. 2017;35(3):246\u201350.","journal-title":"Dig Dis"},{"issue":"4","key":"4549_CR48","doi-asserted-by":"publisher","first-page":"E708","DOI":"10.1210\/jc.2012-3736","volume":"98","author":"R Kohli","year":"2013","unstructured":"Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metabolism. 2013;98(4):E708\u201312.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"4549_CR49","doi-asserted-by":"crossref","unstructured":"Chen X, Lou G, Meng Z, Huang W. TGR5: a novel target for weight maintenance and glucose metabolism. Experimental diabetes research 2011, 2011.","DOI":"10.1155\/2011\/853501"},{"issue":"1","key":"4549_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20080075","volume":"116","author":"Y-Y Yang","year":"2009","unstructured":"Yang Y-Y, Huang Y-T, Lee K-C, Lee F-Y, Lee T-Y, Hou M-C, Lin H-C, Lee S-D. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. Clin Sci. 2009;116(1):71\u20139.","journal-title":"Clin Sci"},{"key":"4549_CR51","unstructured":"Achufusi TGO, Safadi AO, Mahabadi N. Ursodeoxycholic acid. StatPearls [Internet]. edn.: StatPearls Publishing; 2022."},{"issue":"6","key":"4549_CR52","doi-asserted-by":"publisher","first-page":"G872","DOI":"10.1152\/ajpgi.00163.2019","volume":"317","author":"SJ Keely","year":"2019","unstructured":"Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiology-Gastrointestinal Liver Physiol. 2019;317(6):G872\u201381.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"4","key":"4549_CR53","first-page":"1365","volume":"3","author":"A Kay","year":"2011","unstructured":"Kay A, Richardson J, Forsyth NR. Physiological normoxia and chondrogenic potential of chondrocytes. Front Bioscience-Elite. 2011;3(4):1365\u201374.","journal-title":"Front Bioscience-Elite"},{"key":"4549_CR54","doi-asserted-by":"crossref","unstructured":"Chiang JY. Bile acids: regulation of synthesis: thematic review series: bile acids. J Lipid Res 2009, 50(10):1955\u201366.","DOI":"10.1194\/jlr.R900010-JLR200"},{"issue":"9","key":"4549_CR55","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/gut.32.9.1061","volume":"32","author":"J De Caestecker","year":"1991","unstructured":"De Caestecker J, Jazrawi R, Petroni M, Northfield T. Ursodeoxycholic acid in chronic liver disease. Gut. 1991;32(9):1061\u20135.","journal-title":"Gut"},{"issue":"1","key":"4549_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1041-4","volume":"18","author":"LE Simental-Mend\u00eda","year":"2019","unstructured":"Simental-Mend\u00eda LE, Simental-Mend\u00eda M, S\u00e1nchez-Garc\u00eda A, Banach M, Serban M-C, Cicero AF, Sahebkar A. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019;18(1):1\u201313.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"4549_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.apsb.2015.01.006","volume":"5","author":"JM Ridlon","year":"2015","unstructured":"Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sinica B. 2015;5(2):99\u2013105.","journal-title":"Acta Pharm Sinica B"},{"issue":"3","key":"4549_CR58","first-page":"259","volume":"14","author":"I Copaci","year":"2005","unstructured":"Copaci I, Micu L, Iliescu L, Voiculescu M. New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol. 2005;14(3):259\u201366.","journal-title":"Rom J Gastroenterol"},{"issue":"2","key":"4549_CR59","doi-asserted-by":"publisher","first-page":"e0246161","DOI":"10.1371\/journal.pone.0246161","volume":"16","author":"JA Winston","year":"2021","unstructured":"Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS ONE. 2021;16(2):e0246161.","journal-title":"PLoS ONE"},{"key":"4549_CR60","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","volume":"9","author":"S Fiorucci","year":"2018","unstructured":"Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile acids activated receptors regulate innate immunity. Front Immunol. 2018;9:1853.","journal-title":"Front Immunol"},{"issue":"11","key":"4549_CR61","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","volume":"21","author":"S Fiorucci","year":"2015","unstructured":"Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med. 2015;21(11):702\u201314.","journal-title":"Trends Mol Med"},{"issue":"1","key":"4549_CR62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.celrep.2018.12.028","volume":"26","author":"K Wang","year":"2019","unstructured":"Wang K, Liao M, Zhou N, Bao L, Ma K, Zheng Z, Wang Y, Liu C, Wang W, Wang J. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 2019;26(1):222\u201335. e225.","journal-title":"Cell Rep"},{"issue":"2","key":"4549_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3760","volume":"21","author":"S Fang","year":"2015","unstructured":"Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21(2):159\u201365.","journal-title":"Nat Med"},{"issue":"7413","key":"4549_CR64","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nature11400","volume":"488","author":"I Cho","year":"2012","unstructured":"Cho I, Yamanishi S, Cox L, Meth\u00e9 BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621\u20136.","journal-title":"Nature"},{"key":"4549_CR65","doi-asserted-by":"crossref","unstructured":"Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP. A core gut microbiome in obese and lean twins. nature 2009, 457(7228):480\u2013484.","DOI":"10.1038\/nature07540"},{"key":"4549_CR66","doi-asserted-by":"crossref","unstructured":"Hateley C, Olona A, Halliday L, Edin ML, Ko J-H, Forlano R, Terra X, Lih FB, Beltr\u00e1n-Deb\u00f3n R, Manousou P. Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity. EBioMedicine 2024, 103.","DOI":"10.1016\/j.ebiom.2024.105127"},{"key":"4549_CR67","doi-asserted-by":"publisher","first-page":"105293","DOI":"10.1016\/j.ebiom.2024.105293","volume":"107","author":"S Adam","year":"2024","unstructured":"Adam S, Maas SL, Huchzermeier R, Rakateli L, Abschlag K, Hohl M, Liao L, Bartneck M, Teunissen M, Wouters K, et al. The calcium-sensing-receptor (CaSR) in adipocytes contributes to sex-differences in the susceptibility to high fat diet induced obesity and atherosclerosis. EBioMedicine. 2024;107:105293.","journal-title":"EBioMedicine"},{"key":"4549_CR68","doi-asserted-by":"crossref","unstructured":"Stinson SE, Reim PK, Lund MAV, Lausten-Thomsen U, Holm LA, Huang Y, Br\u00f8ns C, Vaag A, Thiele M, Krag A. The interplay between birth weight and obesity in determining childhood and adolescent cardiometabolic risk. EBioMedicine 2024, 105.","DOI":"10.1016\/j.ebiom.2024.105205"},{"issue":"01","key":"4549_CR69","first-page":"28","volume":"125","author":"H Al-Salami","year":"2017","unstructured":"Al-Salami H, Mamo J, Mooranian A, Negrulj R, Lam V, Elahy M, Takechi R. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exp Clin Endocrinol Diabetes. 2017;125(01):28\u201332.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"4549_CR70","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ajg.2009.661","volume":"105","author":"A Berzigotti","year":"2010","unstructured":"Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Sp\u00e9nard J, Bosch J. NCX-1000, a nitric oxide\u2013releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Official J Am Coll Gastroenterology| ACG. 2010;105(5):1094\u2013101.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"key":"4549_CR71","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.5604\/01.3001.0010.5500","volume":"16","author":"JP Arab","year":"2017","unstructured":"Arab JP, Barrera F, Arrese M. Bile acids and portal hypertension. Ann Hepatol. 2017;16:S83\u20136.","journal-title":"Ann Hepatol"},{"issue":"6","key":"4549_CR72","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/ijo.2017.57","volume":"41","author":"J Mamo","year":"2017","unstructured":"Mamo J, Lam V, Giles C, Coulson S, Fimognari N, Mooranian A, Al-Salami H, Takechi R. Antihypertensive agents do not prevent blood\u2013brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. Int J Obes. 2017;41(6):926\u201334.","journal-title":"Int J Obes"},{"issue":"8","key":"4549_CR73","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jch.14688","volume":"25","author":"M Karakayali","year":"2023","unstructured":"Karakayali M, Omar T, Artac I, Rencuzogullari I, Karabag Y, Demir O. The relationship between the systemic immune-inflammation index and reverse\u2010dipper circadian pattern in newly diagnosed hypertensive patients. J Clin Hypertens. 2023;25(8):700\u20137.","journal-title":"J Clin Hypertens"},{"key":"4549_CR74","doi-asserted-by":"publisher","first-page":"e20230540","DOI":"10.36660\/abc.20230540","volume":"121","author":"M Karakayali","year":"2024","unstructured":"Karakayali M, Altunova M, Yakisan T, Aslan S, Omar T, Artac I, Ilis D, Arslan A, Cagin Z, Karabag Y. The relationship between the systemic Immune-inflammation index and ischemia with non-obstructive coronary arteries in patients undergoing coronary angiography. Arquivos brasileiros de cardiologia. 2024;121:e20230540.","journal-title":"Arquivos brasileiros de cardiologia"},{"issue":"2","key":"4549_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5483\/BMBRep.2016.49.2.173","volume":"49","author":"A-R Oh","year":"2016","unstructured":"Oh A-R, Bae J-S, Lee J, Shin E, Oh B-C, Park S-C, Cha J-Y. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep. 2016;49(2):105.","journal-title":"BMB Rep"},{"key":"4549_CR76","doi-asserted-by":"publisher","first-page":"117760","DOI":"10.1016\/j.lfs.2020.117760","volume":"254","author":"FE Ali","year":"2020","unstructured":"Ali FE, Hassanein EH, Bakr AG, El-Shoura EA, El-Gamal DA, Mahmoud AR, Abd-Elhamid TH. Ursodeoxycholic acid abrogates gentamicin-induced hepatotoxicity in rats: role of NF-\u03baB-p65\/TNF-\u03b1, Bax\/Bcl-xl\/Caspase-3, and eNOS\/iNOS pathways. Life Sci. 2020;254:117760.","journal-title":"Life Sci"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04549-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:52:58Z","timestamp":1740106378000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4549"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04549-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}